Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02343679 |
| Title | Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies |
| Recruitment | Withdrawn |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | Anne Beaven, MD |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
CKB BOOST